{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:38:51Z","timestamp":1778636331049,"version":"3.51.4"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T00:00:00Z","timestamp":1514419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21534008"],"award-info":[{"award-number":["21534008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61673143"],"award-info":[{"award-number":["61673143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372213"],"award-info":[{"award-number":["81372213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572935"],"award-info":[{"award-number":["81572935"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Synthetic lethal (SL) interactions occur when alterations in two genes lead to cell death but alteration in only one of them is not lethal. SL interactions provide a new strategy for molecular-targeted cancer therapy. Currently, there are few drugs targeting SL interactions that entered into clinical trials. Therefore, it is necessary to investigate the link between SL interactions and drug sensitivity of cancer cells systematically for drug development purpose. We identified SL interactions by integrating the high-throughput data from The Cancer Genome Atlas, small hairpin RNA data and genetic interactions of yeast. By integrating SL interactions from other studies, we tested whether the SL pairs that consist of drug target genes and the genes with genomic alterations are related with drug sensitivity of cancer cells. We found that only 6.26%\u223c34.61% of SL interactions showed the expected significant drug sensitivity using the pooled cancer cell line data from different tissues, but the proportion increased significantly to approximately 90% using the cancer cell line data for each specific tissue. From an independent pharmacogenomics data of 41 breast cancer cell lines, we found three SL interactions (ABL1\u2013IFI16, ABL1\u2013SLC50A1 and ABL1\u2013SYT11) showed significantly better prognosis for the patients with both genes being altered than the patients with only one gene being altered, which partially supports the SL effect between the gene pairs. Our study not only provides a new way for unraveling the complex mechanisms of drug sensitivity but also suggests numerous potentially important drug targets for cancer therapy.<\/jats:p>","DOI":"10.1093\/bib\/bbx172","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T21:31:21Z","timestamp":1513373481000},"page":"1295-1307","source":"Crossref","is-referenced-by-count":12,"title":["Link synthetic lethality to drug sensitivity of cancer cells"],"prefix":"10.1093","volume":"20","author":[{"given":"Ruiping","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangxiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianlong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lishuang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"issue":"1","key":"2019100807484941500_bbx172-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.febslet.2010.11.024","article-title":"Synthetic lethality: general principles, utility and detection using genetic screens in human cells","volume":"585","author":"Nijman","year":"2011","journal-title":"FEBS Lett"},{"issue":"12","key":"2019100807484941500_bbx172-B2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.molmed.2014.09.009","article-title":"Building high-resolution synthetic lethal networks: a \u2032Google map\u2032 of the cancer cell","volume":"20","author":"Paul","year":"2014","journal-title":"Trends Mol Med"},{"issue":"5","key":"2019100807484941500_bbx172-B3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrd3374","article-title":"Harnessing synthetic lethal interactions in anticancer drug discovery","volume":"10","author":"Chan","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2019100807484941500_bbx172-B4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12943-016-0546-y","article-title":"Synthetic lethality in lung cancer and translation to clinical therapies","volume":"15","author":"Leung","year":"2016","journal-title":"Mol Cancer"},{"issue":"2","key":"2019100807484941500_bbx172-B5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2019100807484941500_bbx172-B6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/bjc.2016.67","article-title":"PARP inhibitors: the race is on","volume":"114","author":"Brown","year":"2016","journal-title":"Br J Cancer"},{"issue":"7","key":"2019100807484941500_bbx172-B7","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1038\/bjc.2016.133","article-title":"Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer","volume":"114","author":"Drew","year":"2016","journal-title":"Br J Cancer"},{"issue":"30","key":"2019100807484941500_bbx172-B8","doi-asserted-by":"crossref","first-page":"12372","DOI":"10.1073\/pnas.1109363108","article-title":"Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer","volume":"108","author":"Cheung","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019100807484941500_bbx172-B9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/msb.2013.54","article-title":"A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities","volume":"9","author":"Vizeacoumar","year":"2014","journal-title":"Mol Syst Biol"},{"issue":"20","key":"2019100807484941500_bbx172-B10","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1158\/0008-5472.CAN-12-3956","article-title":"A comparative genomic approach for identifying synthetic lethal interactions in human cancer","volume":"73","author":"Deshpande","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"2019100807484941500_bbx172-B11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13062-015-0086-1","article-title":"Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer","volume":"10","author":"Srihari","year":"2015","journal-title":"Biol Direct"},{"issue":"2","key":"2019100807484941500_bbx172-B12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1158\/2159-8290.CD-11-0224","article-title":"Essential gene profiles in breast, pancreatic, and ovarian cancer cells","volume":"2","author":"Marcotte","year":"2012","journal-title":"Cancer Discov"},{"issue":"1","key":"2019100807484941500_bbx172-B13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/msb.2011.35","article-title":"Predicting selective drug targets in cancer through metabolic networks","volume":"7","author":"Folger","year":"2014","journal-title":"Mol Syst Biol"},{"issue":"5","key":"2019100807484941500_bbx172-B14","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.cell.2014.07.027","article-title":"Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality","volume":"158","author":"Jerby-Arnon","year":"2014","journal-title":"Cell"},{"key":"2019100807484941500_bbx172-B15","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/ncomms3124","article-title":"Genome evolution predicts genetic interactions in protein complexes and reveals cancer drug targets","volume":"4","author":"Lu","year":"2013","journal-title":"Nat Commun"},{"issue":"03","key":"2019100807484941500_bbx172-B16","doi-asserted-by":"crossref","first-page":"1541002","DOI":"10.1142\/S0219720015410024","article-title":"Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates","volume":"13","author":"Zhang","year":"2015","journal-title":"J Bioinform Comput Biol"},{"issue":"D1","key":"2019100807484941500_bbx172-B17","doi-asserted-by":"crossref","first-page":"D1011","DOI":"10.1093\/nar\/gkv1108","article-title":"SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets","volume":"44","author":"Guo","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2019100807484941500_bbx172-B18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.molcel.2016.06.022","article-title":"A network of conserved synthetic lethal interactions for exploration of precision cancer therapy","volume":"63","author":"Srivas","year":"2016","journal-title":"Mol Cell"},{"issue":"8","key":"2019100807484941500_bbx172-B19","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1039\/c3mb25589a","article-title":"Identification of synthetic lethal pairs in biological systems through network information centrality","volume":"9","author":"Kranthi","year":"2013","journal-title":"Mol Biosyst"},{"issue":"1","key":"2019100807484941500_bbx172-B20","doi-asserted-by":"crossref","first-page":"30.","DOI":"10.1186\/1755-8794-6-30","article-title":"Identification of potential synthetic lethal genes to p53 using a computational biology approach","volume":"6","author":"Wang","year":"2013","journal-title":"BMC Med Genomics"},{"issue":"34","key":"2019100807484941500_bbx172-B21","doi-asserted-by":"crossref","first-page":"55352","DOI":"10.18632\/oncotarget.10536","article-title":"Ranking novel cancer driving synthetic lethal gene pairs using TCGA data","volume":"7","author":"Ye","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"2019100807484941500_bbx172-B22","doi-asserted-by":"crossref","first-page":"824.","DOI":"10.15252\/msb.20156102","article-title":"Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types","volume":"11","author":"Park","year":"2015","journal-title":"Mol Syst Biol"},{"key":"2019100807484941500_bbx172-B23","first-page":"196034","article-title":"Syn-lethality: an integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies","volume":"2014","author":"Li","year":"2014","journal-title":"Biomed Res Int"},{"key":"2019100807484941500_bbx172-B24","doi-asserted-by":"crossref","first-page":"D470","DOI":"10.1093\/nar\/gku1204","article-title":"The BioGRID interaction database: 2015 update","volume":"43","author":"Chatr-Aryamontri","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2019100807484941500_bbx172-B25","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbw142","article-title":"A landscape of synthetic viable interactions in cancer","author":"Gu","year":"2017","journal-title":"Brief Bioinform"},{"issue":"5844","key":"2019100807484941500_bbx172-B26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1126\/science.1138764","article-title":"Comment on \u201cThe consensus coding sequences of human breast and colorectal cancers\u201d","volume":"317","author":"Getz","year":"2007","journal-title":"Science"},{"issue":"50","key":"2019100807484941500_bbx172-B27","doi-asserted-by":"crossref","first-page":"20007","DOI":"10.1073\/pnas.0710052104","article-title":"Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma","volume":"104","author":"Beroukhim","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7391","key":"2019100807484941500_bbx172-B28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"issue":"5964","key":"2019100807484941500_bbx172-B29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1180823","article-title":"The genetic landscape of a cell","volume":"327","author":"Costanzo","year":"2010","journal-title":"Science"},{"issue":"Database issue","key":"2019100807484941500_bbx172-B30","doi-asserted-by":"crossref","first-page":"D196","DOI":"10.1093\/nar\/gkp931","article-title":"InParanoid 7: new algorithms and tools for eukaryotic orthology analysis","volume":"38","author":"Ostlund","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2019100807484941500_bbx172-B31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/00031305.1948.10483405","article-title":"Questions and answers","volume":"2","author":"Mosteller","year":"1948","journal-title":"Am Stat"},{"issue":"2","key":"2019100807484941500_bbx172-B32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nchembio.1986","article-title":"Correlating chemical sensitivity and basal gene expression reveals mechanism of action","volume":"12","author":"Rees","year":"2015","journal-title":"Nat Chem Biol"},{"key":"2019100807484941500_bbx172-B33","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2019100807484941500_bbx172-B34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/1471-2164-10-277","article-title":"CellMiner: a relational database and query tool for the NCI-60 cancer cell lines","volume":"10","author":"Shankavaram","year":"2009","journal-title":"BMC Genomics"},{"issue":"7403","key":"2019100807484941500_bbx172-B35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"issue":"1","key":"2019100807484941500_bbx172-B36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cell.2011.03.020","article-title":"Genetic interactions in cancer progression and treatment","volume":"145","author":"Ashworth","year":"2011","journal-title":"Cell"},{"issue":"Database issue","key":"2019100807484941500_bbx172-B37","doi-asserted-by":"crossref","first-page":"D1091","DOI":"10.1093\/nar\/gkt1068","article-title":"DrugBank 4.0: shedding new light on drug metabolism","volume":"42","author":"Law","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2019100807484941500_bbx172-B38","first-page":"937","article-title":"Proteomic response to 5, 6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach","volume":"9","author":"Pan","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"2019100807484941500_bbx172-B39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.coph.2008.08.004","article-title":"Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises","volume":"8","author":"Yap","year":"2008","journal-title":"Curr Opin Pharmacol"},{"issue":"D1","key":"2019100807484941500_bbx172-B40","doi-asserted-by":"crossref","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: new perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"Kanehisa","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2019100807484941500_bbx172-B41","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/gb-2013-14-10-r110","article-title":"Modeling precision treatment of breast cancer","volume":"14","author":"Daemen","year":"2013","journal-title":"Genome Biol"},{"issue":"6306","key":"2019100807484941500_bbx172-B42","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf1420","article-title":"A global genetic interaction network maps a wiring diagram of cellular function","volume":"353","author":"Costanzo","year":"2016","journal-title":"Science"},{"issue":"16","key":"2019100807484941500_bbx172-B43","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.ejca.2010.07.031","article-title":"A lethal combination for cancer cells: synthetic lethality screenings for drug discovery","volume":"46","author":"Ferrari","year":"2010","journal-title":"Eur J Cancer"},{"issue":"10","key":"2019100807484941500_bbx172-B44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nmeth1006-777","article-title":"Minimizing the risk of reporting false positives in large-scale RNAi screens","volume":"3","author":"Echeverri","year":"2006","journal-title":"Nat Methods"},{"issue":"2","key":"2019100807484941500_bbx172-B45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1101\/gr.125567.111","article-title":"Mutual exclusivity analysis identifies oncogenic network modules","volume":"22","author":"Ciriello","year":"2012","journal-title":"Genome Res"},{"issue":"48","key":"2019100807484941500_bbx172-B46","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1073\/pnas.1314302110","article-title":"Synthetic lethality between CCNE1 amplification and loss of BRCA1","volume":"110","author":"Etemadmoghadam","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019100807484941500_bbx172-B47","first-page":"63","article-title":"Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data","volume":"19","author":"Jang","year":"2014","journal-title":"Pac Symp Biocomput"},{"issue":"1","key":"2019100807484941500_bbx172-B48","doi-asserted-by":"crossref","first-page":"22120","DOI":"10.1038\/srep22120","article-title":"An integrative pharmacogenomic approach identifies two-drug combination therapies for personalized cancer medicine","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"2019100807484941500_bbx172-B49","doi-asserted-by":"crossref","first-page":"e0133850","DOI":"10.1371\/journal.pone.0133850","article-title":"Context sensitive modeling of cancer drug sensitivity","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"2019100807484941500_bbx172-B50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13059-016-1050-9","article-title":"Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models","volume":"17","author":"Geeleher","year":"2016","journal-title":"Genome Biol"},{"issue":"6","key":"2019100807484941500_bbx172-B51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat Methods"},{"issue":"1","key":"2019100807484941500_bbx172-B52","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1038\/s41598-017-03986-1","article-title":"Prediction of lncRNA-protein interactions using HeteSim scores based on heterogeneous networks","volume":"7","author":"Xiao","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"2019100807484941500_bbx172-B53","doi-asserted-by":"crossref","first-page":"e0179314","DOI":"10.1371\/journal.pone.0179314","article-title":"Accurate prediction of functional effects for variants by combining gradient tree boosting with optimal neighborhood properties","volume":"12","author":"Pan","year":"2017","journal-title":"PLoS One"},{"issue":"S1","key":"2019100807484941500_bbx172-B54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12859-015-0851-2","article-title":"PredRSA: a gradient boosted regression trees approach for predicting protein solvent accessibility","volume":"17","author":"Fan","year":"2016","journal-title":"BMC Bioinformatics"},{"issue":"12","key":"2019100807484941500_bbx172-B55","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1039\/b803806f","article-title":"Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing","volume":"4","author":"Shih","year":"2008","journal-title":"Mol Biosyst"},{"issue":"1","key":"2019100807484941500_bbx172-B56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14728222.2011.641951","article-title":"Targeting the VEGF signaling pathway in cancer therapy","volume":"16","author":"Waldner","year":"2012","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"2019100807484941500_bbx172-B57","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3892\/ijo.2015.2982","article-title":"Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6","volume":"47","author":"Yi","year":"2015","journal-title":"Int J Oncol"},{"key":"2019100807484941500_bbx172-B58","doi-asserted-by":"crossref","first-page":"15580","DOI":"10.1038\/ncomms15580","article-title":"Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data","volume":"8","author":"Sinha","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2019100807484941500_bbx172-B59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s13059-016-1114-x","article-title":"A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence","volume":"17","author":"Canisius","year":"2016","journal-title":"Genome Biol"},{"key":"2019100807484941500_bbx172-B60","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1038\/ncomms5828","article-title":"Widespread genetic epistasis among cancer genes","volume":"5","author":"Wang","year":"2014","journal-title":"Nat Commun"},{"issue":"1","key":"2019100807484941500_bbx172-B61","doi-asserted-by":"crossref","first-page":"e8569","DOI":"10.1371\/journal.pone.0008569","article-title":"Interferon-inducible IFI16, a negative regulator of cell growth, down-regulates expression of human telomerase reverse transcriptase (hTERT) gene","volume":"5","author":"Song","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"2019100807484941500_bbx172-B62","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/annonc\/mdr261","article-title":"Phase II study of single-agent bosutinib, a Src\/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy","volume":"23","author":"Campone","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/20\/4\/1295\/30119753\/bbx172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/20\/4\/1295\/30119753\/bbx172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T19:41:31Z","timestamp":1719690091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/20\/4\/1295\/4781362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,28]]},"references-count":62,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,12,28]]},"published-print":{"date-parts":[[2019,7,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbx172","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2017,12,28]]}}}